Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony G Wilson

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Annals of the Rheumatic Diseases|November 12, 2010
Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosusGisela Orozco, Steve Eyre, Anne Hinks, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association studyGisela Orozco, Sebastien Viatte, John Bowes, et al.
Annals of the Rheumatic Diseases|September 12, 2023
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritisChuan Fu Yap, Nisha Nair, Annick de Vries, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2015
C5orf30 is a negative regulator of tissue damage in rheumatoid arthritisMunitta Muthana, Sarah Hawtree, Adam Wilshaw, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2020
Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic DrugsArianna Dagliati, Darren Plant, Nisha Nair, et al.
Osteoarthritis and Cartilage Open|September 9, 2022
Tibiofemoral knee osteoarthritis progresses symmetrically by knee compartment in the GOGO cohortLouie C Alexander, Janet L Huebner, Greg Cicconetti, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysisSamantha Louise Smith, Sheree Alexander, Nisha Nair, et al.
Rheumatology (Oxford, England)|May 13, 2025
Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritisStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Annals of the Rheumatic Diseases|November 12, 2010
Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosusGisela Orozco, Steve Eyre, Anne Hinks, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association studyGisela Orozco, Sebastien Viatte, John Bowes, et al.
Annals of the Rheumatic Diseases|September 12, 2023
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritisChuan Fu Yap, Nisha Nair, Annick de Vries, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2015
C5orf30 is a negative regulator of tissue damage in rheumatoid arthritisMunitta Muthana, Sarah Hawtree, Adam Wilshaw, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2020
Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic DrugsArianna Dagliati, Darren Plant, Nisha Nair, et al.
Osteoarthritis and Cartilage Open|September 9, 2022
Tibiofemoral knee osteoarthritis progresses symmetrically by knee compartment in the GOGO cohortLouie C Alexander, Janet L Huebner, Greg Cicconetti, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysisSamantha Louise Smith, Sheree Alexander, Nisha Nair, et al.
Rheumatology (Oxford, England)|May 13, 2025
Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritisStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Pageof 12